ACON vs. DHAC, NIVF, BACK, GBNHF, BTTX, UPHL, ACONW, AONC, DHACW, and LFMDP
Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), IMAC (BACK), Greenbrook TMS (GBNHF), Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), and LifeMD (LFMDP). These companies are all part of the "healthcare" industry.
Aclarion vs.
Aclarion (NASDAQ:ACON) and Digital Health Acquisition (NASDAQ:DHAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
7.5% of Aclarion shares are held by institutional investors. Comparatively, 1.0% of Digital Health Acquisition shares are held by institutional investors. 1.5% of Aclarion shares are held by insiders. Comparatively, 6.6% of Digital Health Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Digital Health Acquisition has lower revenue, but higher earnings than Aclarion.
Aclarion currently has a consensus price target of $1.30, suggesting a potential upside of 2,973.29%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts clearly believe Aclarion is more favorable than Digital Health Acquisition.
In the previous week, Aclarion had 3 more articles in the media than Digital Health Acquisition. MarketBeat recorded 4 mentions for Aclarion and 1 mentions for Digital Health Acquisition. Digital Health Acquisition's average media sentiment score of 0.00 beat Aclarion's score of -0.17 indicating that Digital Health Acquisition is being referred to more favorably in the news media.
Aclarion has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Digital Health Acquisition has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
Digital Health Acquisition has a net margin of 0.00% compared to Aclarion's net margin of -12,845.05%. Digital Health Acquisition's return on equity of 0.00% beat Aclarion's return on equity.
Aclarion received 4 more outperform votes than Digital Health Acquisition when rated by MarketBeat users.
Summary
Aclarion beats Digital Health Acquisition on 8 of the 13 factors compared between the two stocks.
Get Aclarion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclarion Competitors List
Related Companies and Tools
This page (NASDAQ:ACON) was last updated on 1/20/2025 by MarketBeat.com Staff
Free ACON Stock Alerts